LN04 - Lymphoma Tissue Microarray
|
|
|
- Arthur Bennett
- 5 years ago
- Views:
Transcription
1 Reveal Biosciences offers Histochemical Staining, Immunohistochemistry (IHC), In Situ Hybridization (ISH), Whole Slide Imaging, and Quantitative Image Analysis on any TMA LN04 - Lymphoma Tissue Microarray A B C D E F G H I J Cases: 75 Cores: 150 Core Size: 1.1mm Core Thickness: 4um Format: 10 x 15 QA/QC: H&E, IHC anti-cytokeratin Normal Benign Malignant Orientation core Description: Lymphoma tissue array, 150 cores from reactive lymphoid tissues (5 cases) and various lymphoma (70 cases) tissues in duplicates. All tissues were fixed in 10% neutral buffer formalin for 24 hours and processed using identical SOPs. Sections were picked onto Superfrost Plus or Startfrost Adhesive slides. All TMAs are cut fresh upon ordering. They all have a guaranteed six month shelf-life at 4 degrees Celsius from the date of shipment. Additional cores not listed are orientation markers and have no data. There may be <5% core loss per slide but the core retention rate should be >90%. Note: Bake at 60 C for 30 minutes before use.
2 A01 M 26.0 Lymph node Reactive A02 M 47.0 Lymph node Reactive A03 M 31.0 Tonsil Reactive A04 M 14.0 Tonsil Reactive A05 F 21.0 Spleen Normal A06 F 77.0 Thyroid MALT B cell lymphoma A07 M 62.0 Stomach Non-Hodgkin lymphoma A08 M 50.0 Intestine, Non-Hodgkin B cell lymphoma A09 M 41.0 Lymph node, Hodgkin lymphoma A10 M 55.0 Lymph node, Peripheral T cell lymphoma, A11 M 54.0 Shoulder Non-Hodgkin B cell lymphoma A12 M 39.0 Lymph node, Non-Hodgkin B cell lymphoma A13 M 5.0 Lymph node Anaplastic large cell lymphoma? A14 M 40.0 Lymph node Hodgkin lymphoma A15 M 48.0 Intestine, Non-Hodgkin B cell lymphoma B01 M 26.0 Lymph node Reactive B02 M 47.0 Lymph node Reactive B03 M 31.0 Tonsil Reactive B04 M 14.0 Tonsil Reactive B05 F 21.0 Spleen Normal B06 F 77.0 Thyroid MALT B cell lymphoma B07 M 62.0 Stomach Non-Hodgkin lymphoma B08 M 50.0 Intestine, Non-Hodgkin B cell lymphoma B09 M 41.0 Lymph node, Hodgkin lymphoma B10 M 55.0 Lymph node, Peripheral T cell lymphoma, B11 M 54.0 Shoulder Non-Hodgkin B cell lymphoma B12 M 39.0 Lymph node, Non-Hodgkin B cell lymphoma B13 M 5.0 Lymph node Anaplastic large cell lymphoma? B14 M 40.0 Lymph node Hodgkin lymphoma B15 M 48.0 Intestine, Non-Hodgkin B cell lymphoma C01 M 60.0 Intestine, Lymphoma, diffuse large B cell C02 M 42.0 Axillary lymph Non-Hodgkin B cell lymphoma C03 M 7.0 Lymph node Hodgkin lymphoma
3 Pos. Sex Age Anatomic Site Pathology Grad Stage (TNM) C04 M 66.0 Lymph node Non-Hodgkin lymphoma C05 M 40.0 Intestine, Lymphoma, non-hodgkin B cell C06 M 33.0 Lymph node, Non-Hodgkin B cell lymphoma C07 M 53.0 Lymph node, Anaplastic large cell lymphoma? C08 F 32.0 Lung lymph Non-Hodgkin B cell lymphoma? C09 M 72.0 Testis Non-Hodgkin B cell lymphoma C10 F 71.0 Lymph node Non-Hodgkin B cell lymphoma C11 M 43.0 Stomach MALT B cell lymphoma, high grade C12 F 52.0 Lymph node, Diffuse large B cell lymphoma C13 M 60.0 Intestine, colon MALT B cell lymphoma? C14 M 30.0 Peritoneal Hodgkin lymphoma C15 F 40.0 Peritoneal Non-Hodgkin B cell lymphoma D01 M 60.0 Intestine, colon Lymphoma, diffuse large B cell D02 M 42.0 Axillary lymph Non-Hodgkin B cell lymphoma D03 M 7.0 Lymph node Hodgkin lymphoma D04 M 66.0 Lymph node Non-Hodgkin lymphoma D05 M 40.0 Intestine, Lymphoma, non-hodgkin B cell D06 M 33.0 Lymph node, Non-Hodgkin B cell lymphoma D07 M 53.0 Lymph node, Anaplastic large cell lymphoma? D08 F 32.0 Lung lymph Non-Hodgkin B cell lymphoma? D09 M 72.0 Testis Non-Hodgkin B cell lymphoma D10 F 71.0 Lymph node Non-Hodgkin B cell lymphoma D11 M 43.0 Stomach MALT B cell lymphoma, high grade D12 F 52.0 Lymph node, Diffuse large B cell lymphoma D13 M 60.0 Intestine, colon MALT B cell lymphoma? D14 M 30.0 Peritoneal Hodgkin lymphoma D15 F 40.0 Peritoneal Non-Hodgkin B cell lymphoma E01 F 33.0 Stomach MALT B cell lymphoma, high grade E02 F 70.0 Lymph node, Non-Hodgkin B cell lymphoma E03 F 43.0 Lymph node, Non-Hodgkin B cell lymphoma E04 M 65.0 Lymph node Non-Hodgkin B cell lymphoma E05 M 76.0 Tonsil Diffuse large B cell lymphoma E06 F 32.0 Pelvic Cavity Non-Hodgkin B cell lymphoma
4 E07 M 39.0 Lymph node, Non-Hodgkin B cell lymphoma E08 M 50.0 Lymph node, Hodgkin lymphoma E09 M 43.0 Intestine, ilium Lymphoma, diffuse large B cell E10 F 53.0 Lymph node, Mantle cell lymphoma E11 F 72.0 Lymph node Non-Hodgkin B cell lymphoma E12 M 53.0 Lymph node, Diffuse large B cell lymphoma E13 F 55.0 Lymph node, Non-Hodgkin lymphoma E14 F 55.0 Breast Lymphoma, diffuse large B cell E15 M 13.0 Shoulder Diffuse large B cell lymphoma F01 F 33.0 Stomach MALT B cell lymphoma, high grade F02 F 70.0 Lymph node, Non-Hodgkin B cell lymphoma F03 F 43.0 Lymph node, Non-Hodgkin B cell lymphoma F04 M 65.0 Lymph node Non-Hodgkin B cell lymphoma F05 M 76.0 Tonsil Diffuse large B cell lymphoma F06 F 32.0 Pelvic Cavity Non-Hodgkin B cell lymphoma F07 M 39.0 Lymph node, Non-Hodgkin B cell lymphoma F08 M 50.0 Lymph node, Hodgkin lymphoma F09 M 43.0 Intestine, ilium Lymphoma, diffuse large B cell F10 F 53.0 Lymph node, Mantle cell lymphoma F11 F 72.0 Lymph node Non-Hodgkin B cell lymphoma F12 M 53.0 Lymph node, Diffuse large B cell lymphoma F13 F 55.0 Lymph node, Non-Hodgkin lymphoma F14 F 55.0 Breast Lymphoma, diffuse large B cell F15 M 13.0 Shoulder Diffuse large B cell lymphoma G01 M 35.0 Lymph node Non-Hodgkin B cell lymphoma G02 M 40.0 Tonsil Non-Hodgkin B cell lymphoma G03 F 54.0 Lymph node Hodgkin lymphoma G04 M 24.0 Intestine, ilium- Non-Hodgkin B cell lymphoma G05 M 64.0 Lymph node Non-Hodgkin B cell lymphoma G06 M 49.0 Lymph node, Hodgkin lymphoma G07 M 65.0 Stomach MALT B cell lymphoma, high grade G08 M 73.0 Kidney Lymphoma, diffuse large B cell G09 M 4.0 Lymph node, Non-Hodgkin B cell lymphoma
5 G10 F 70.0 Intestine, ilium Lymphoma, diffuse large B cell G11 F 52.0 Lung Non-Hodgkin lymphoma G12 M 51.0 Stomach Non-Hodgkin B cell lymphoma G13 M 28.0 Intestine, ileum Lymphoma, diffuse large B cell G14 F 58.0 Stomach MALT B cell lymphoma, high grade G15 M 38.0 Lymph node Non-Hodgkin B cell lymphoma H01 M 35.0 Lymph node Non-Hodgkin B cell lymphoma H02 M 40.0 Tonsil Non-Hodgkin B cell lymphoma H03 F 54.0 Lymph node Hodgkin lymphoma H04 M 24.0 Intestine, ilium- Non-Hodgkin B cell lymphoma H05 M 64.0 Lymph node Non-Hodgkin B cell lymphoma H06 M 49.0 Lymph node, Hodgkin lymphoma H07 M 65.0 Stomach MALT B cell lymphoma, high grade H08 M 73.0 Kidney Lymphoma, diffuse large B cell H09 M 4.0 Lymph node, Non-Hodgkin B cell lymphoma H10 F 70.0 Intestine, ilium Lymphoma, diffuse large B cell H11 F 52.0 Lung Non-Hodgkin lymphoma H12 M 51.0 Stomach Non-Hodgkin B cell lymphoma H13 M 28.0 Intestine, ileum Lymphoma, diffuse large B cell H14 F 58.0 Stomach MALT B cell lymphoma, high grade H15 M 38.0 Lymph node Non-Hodgkin B cell lymphoma I01 F 58.0 Stomach MALT B cell lymphoma, high grade I02 M 67.0 Lymph node Non-Hodgkin lymphoma I03 F 53.0 Stomach MALT B cell lymphoma, high grade I04 M 73.0 Lymph node Hodgkin lymphoma I05 M 17.0 Intestine, small Non-Hodgkin B cell lymphoma I06 M 43.0 Brain Non-Hodgkin B cell lymphoma I07 M 43.0 Lymph node, Non-Hodgkin B cell lymphoma I08 M 76.0 Lymph node, Non-Hodgkin B cell lymphoma I09 F 51.0 Lymph node, Hodgkin lymphoma I10 F 74.0 Lymph node, Non-Hodgkin lymphoma I11 M 57.0 Lymph node, Hodgkin lymphoma I12 F 42.0 Breast Non-Hodgkin B cell lymphoma
6 I13 M 54.0 Lymph node, Hodgkin lymphoma I14 F 13.0 Lymph node, Hodgkin lymphoma I15 M 31.0 Peritoneal Anaplastic large cell lymphoma J01 F 58.0 Stomach MALT B cell lymphoma, high grade J02 M 67.0 Lymph node Non-Hodgkin lymphoma J03 F 53.0 Stomach MALT B cell lymphoma, high grade J04 M 73.0 Lymph node Hodgkin lymphoma J05 M 17.0 Intestine, small Non-Hodgkin B cell lymphoma J06 M 43.0 Brain Non-Hodgkin B cell lymphoma J07 M 43.0 Lymph node, Non-Hodgkin B cell lymphoma J08 M 76.0 Lymph node, Non-Hodgkin B cell lymphoma J09 F 51.0 Lymph node, Hodgkin lymphoma J10 F 74.0 Lymph node, Non-Hodgkin lymphoma J11 M 57.0 Lymph node, Hodgkin lymphoma J12 F 42.0 Breast Non-Hodgkin B cell lymphoma J13 M 54.0 Lymph node, Hodgkin lymphoma J14 F 13.0 Lymph node, Hodgkin lymphoma J15 M 31.0 Peritoneal Anaplastic large cell lymphoma
CC01 - Colon Cancer Tissue Microarray
Reveal Biosciences offers Histochemical Staining, Immunohistochemistry (IHC), In Situ Hybridization (ISH), Whole Slide Imaging, and Quantitative Image Analysis on any TMA CC01 - Colon Cancer Tissue Microarray
MT09 - Normal Human Tissue Microarray, FDA
Reveal Biosciences offers Histochemical Staining, Immunohistochemistry (IHC), In Situ Hybridization (ISH), Whole Slide Imaging, and Quantitative Image Analysis on any TMA MT09 - Normal Human Tissue Microarray,
ab Lymphoma tissue array of 102 cases (1.5mm) set 2
ab178213 oma tissue array of 102 cases (1.5mm) set 2 Instructions for Use Designed for IHC or ISH based protein or RNA tissue profiling in diffuse large B cell lymphoma/non-hodgkin B cell lymphomas. This
Ab T cell lymphoma tissue array, 75 cases, 150 samples (1.1mm), set 3
Ab204541 T cell tissue array, 75 cases, 150 samples (1.1mm), set 3 Instructions for Use Designed for IHC or ISH based protein or RNA tissue profiling in various s. This product is for research use only
ab Lymphoma tissue array of 102 cases (1.5mm) set 1
ab178212 Lymphoma tissue array of 102 cases (1.5mm) set 1 Instructions for Use Designed for IHC or ISH based protein or RNA tissue profiling in cell lymphoma/non-hodgkin B s. This product is for research
ab Stomach cancer tissue array of 228 cases (1.1mm)
ab178293 Stomach cancer tissue array of 228 cases (1.1mm) Instructions for Use Designed for IHC or ISH based protein or RNA tissue profiling in stomach cancers. This product is for research use only and
Multi-normal human tissues, FDA, 96 samples, 35 organs/sites from three individuals (1.5mm)
ab178228 Multi-normal human tissues, FDA, 96 samples, 35 organs/sites from three individuals (1.5mm) Instructions for Use Designed for antibody cross reactivity analysis and IHC or ISH based protein or
ab Colon cancer tissue array with progressive changes, 48 cases, 96 samples (1.5mm), set 1
ab178131 Colon cancer tissue array with progressive changes, 48 cases, 96 samples (1.5mm), set 1 Instructions for Use Designed for IHC or ISH based protein or RNA tissue profiling in evolution and progression
H&E, IHC anti- Cytokeratin
Cat No: OVC2281 - Ovary cancer tissue array Lot# Cores Size Cut Format QA/QC OVC228101 228 1.1mm 4um 12X19 H&E, IHC anti- Cytokeratin Recommended applications: For Research use only. RNA or protein ovary
ab Prostate cancer tissue array, 24 cases, 48 samples (1.5mm)
ab178263 Prostate cancer tissue array, 24 cases, 48 samples (1.5mm) Instructions for Use Designed for IHC or ISH based protein or RNA tissue profiling in prostate carcinoma. This product is for research
ab Thyroid cancer tissue array, 75 cases, 150 samples (1.1mm), set 1
ab178305 Thyroid cancer tissue array, 75 cases, 150 samples (1.1mm), set 1 Instructions for Use Designed for IHC or ISH based protein or RNA tissue profiling in thyroid cancers. This product is for research
ab Kidney cancer tissue array of 102 cases (1.5mm)
ab178177 Kidney cancer tissue array of 102 cases (1.5mm) Instructions for Use Designed for IHC or ISH based protein or RNA tissue profiling in kidney cancers. This product is for research use only and
ab Head and neck tumor tissue array, 48 cases, 96 samples (1.5mm), set 1
ab178174 neck tumor tissue array, 48 cases, 96 samples (1.5mm), set 1 Instructions for Use Designed for IHC or ISH based protein or RNA tissue profiling in various head and neck tumors. This product is
ab Colon cancer tissue array of 228 cases (1.1mm)
ab178127 Colon cancer tissue array of 228 cases (1.1mm) Instructions for Use Designed for IHC or ISH based protein or RNA tissue profiling in various cancers. This product is for research use only and
Testis/ovary germ cell tumor tissue array, 48 cases, 96 samples
ab178303 Testis/ovary germ cell tumor tissue array, 48 cases, 96 samples Instructions for Use Designed for IHC or ISH based protein or RNA tissue profiling in various testis tumors. This product is for
ab Nervous system tumor tissue array, 48 cases, 96 samples (1.5mm)
ab178246 Nervous system tumor tissue array, 48 cases, 96 samples (1.5mm) Instructions for Use Designed for IHC or ISH based protein or RNA tissue profiling in various tumors of the nervous system. This
ab Tonsillitis tissue array 114 cases 228 samples (1.1mm)
ab178312 - Tonsillitis tissue array 114 cases 228 samples (1.1mm) Instructions for Use Designed for IHC or ISH based protein or RNA tissue profiling in reactive tonsils. This product is for research use
ab Pancreatic cancer tissue array, 24 cases, 48 samples (2mm)
ab178258 Pancreatic cancer tissue array, 24 cases, 48 samples (2mm) Instructions for Use Designed for IHC or ISH based protein or RNA tissue profiling in pancreas cancers. This product is for research
ab Nervous system tumor tissue array, 102 cases (1.5mm)
ab178245 Nervous system tumor tissue array, 102 cases (1.5mm) Instructions for Use Designed for IHC or ISH based protein or RNA tissue profiling in various tumors of the nervous system. This product is
ab Melanoma (primary and metastatic) tissue array, 48 cases, 96 samples (1.5mm)
ab178218 Melanoma (primary and metastatic) tissue array, 48 cases, 96 samples (1.5mm) Instructions for Use Designed for IHC or ISH based protein or RNA tissue profiling in s. This product is for research
Nasopharyngeal primary and metastatic carcinoma tissue array, 96 samples (1.5mm), set 1
ab178243 Nasopharyngeal primary and metastatic tissue array, 96 samples (1.5mm), set 1 Instructions for Use Designed for comparative IHC or ISH based protein or RNA tissue profiling in paired normal, primary
ab Nervous system glioma tissue array, 48 cases, 96 samples (1.5mm)
ab178236 Nervous system glioma tissue array, 48 cases, 96 samples (1.5mm) Instructions for Use Designed for IHC or ISH based protein or RNA tissue profiling in gliomas. This product is for research use
ab Lung cancer tissue array paired with normal tissues, 16 cases, 48 samples (2mm), set 2
ab178192 Lung cancer tissue array paired with normal tissues, 16 cases, 48 samples (2mm), set 2 Instructions for Use Designed for IHC or ISH based protein or RNA tissue profiling in lung cancers. This
ab Lung cancer tissue array, 75 cases, 150 samples (1.1mm), set 1
ab178187 Lung cancer tissue array, 75 cases, 150 samples (1.1mm), set 1 Instructions for Use Designed for IHC or ISH based protein or RNA tissue profiling in lung cancers. This product is for research
Breast cancer tissue array with progressive changes, 48 cases, 96 samples (1.5mm), set 1
ab178111 Breast cancer tissue array with progressive, 48 cases, 96 samples (1.5mm), set 1 nstructions for Use Designed for HC or SH based protein or RNA tissue profiling in evolution and progression of
ab Endometrial cancer tissue array of 102 cases (1.5mm)
ab178148 Endometrial cancer tissue array of 102 cases (1.5mm) Instructions for Use For IHC or ISH based protein or RNA tissue profiling in various cancers. This product is for research use only and is
ab Breast cancer tissue array with progressive changes, 48 cases, 96 samples (1.5mm), set 2
ab178112 Breast cancer tissue array with progressive changes, 48 cases, 96 samples (1.5mm), set 2 nstructions for Use Designed for HC or SH based protein or RNA tissue profiling in evolution and progression
ab Endometrial cancer tissue array, 75 cases, 150 samples (1.1mm), set 1
ab178149 Endometrial cancer tissue array, 75 cases, 150 samples (1.1mm), set 1 Instructions for Use For IHC or ISH based protein or RNA tissue profiling in various cancers. This product is for research
ab Soft tissue tumor tissue array, 48 cases, 96 samples (1.5mm), set 1
ab178280 Soft tumor array, 48 cases, 96 samples (1.5mm), set 1 Instructions for Use Designed for IHC or ISH based protein or RNA profiling in various soft s. This product is for research use only and is
ab Skin tumor tissue array, 75 cases, 150 samples (1.1mm)
ab178285 Skin tumor tissue array, 75 cases, 150 samples (1.1mm) nstructions for Use Designed for HC or SH based protein or RNA tissue profiling in various skin tumors. This product is for research use
ab Cervical cancer tissue array with progressive changes, 48 cases, 96 samples (1.5mm), set 2
ab178144 Cervical cancer tissue array with progressive changes, 48 cases, 96 samples (1.5mm), set 2 Instructions for Use Cervical cancer tissue array set from normal, premalignant and cancer tissues with
Gastrointestinal stromal tumor (GIST) tissue array, 24 cases, 48 samples (2mm)
ab178171 stromal tumor () tissue array, 24 cases, 48 samples (2mm) nstructions for Use Designed for HC or SH based protein or RNA tissue profiling in various gastrointestinal stromal tumors. This product
ab Ovary cancer tissue array of 102 cases (1.5mm)
ab178247 Ovary cancer tissue array of 102 cases (1.5mm) nstructions for Use Designed for HC or SH based protein or RNA tissue profiling in ovary cancers. This product is for research use only and is not
ab Cervical cancer tissue array paired with normal tissue, 16 cases, 48 samples, (2mm).
ab178142 Cervical cancer tissue array paired with normal tissue, 16 cases, 48 samples, (2mm). Instructions for Use Cervical cancer tissue array, 16 cases, 48 cores, one normal paired with two tumor tissue
ab Lung cancer tissue array with progressive changes, 48 cases, 96 samples (1.5mm), set 2
ab178195 Lung cancer tissue array with progressive changes, 48 cases, 96 samples (1.5mm), set 2 nstructions for Use Designed for HC or SH based protein or RNA tissue profiling in evolution and progression
ab Head and neck tumor tissue array, 102 cases (1.5mm)
ab178173 Head and neck tumor tissue array, 102 cases (1.5mm) nstructions for Use Designed for HC or SH based protein or RNA tissue profiling in various head and neck tumors. This product is for research
IMPC phenotyping SOPs in JMC
IMPC phenotyping SOPs in JMC Tissue Embedding and Block Banking IMPC_BLK_001 Purpose Collect and fix a standard list of tissues from the complete necropsy (see IMPC Gross Pathology & Tissue Collection
Cancer Program Report 2014
Cancer Program Report 2014 Queen of the Valley Hospital St Joseph Health Queen of the Valley Hospital - 2014 Site Table Site Total Class Sex Group Cases Analytic NonAn M F 0 I II ALL SITES 661 494 167
Cancer in Estonia 2014
Cancer in Estonia 2014 Estonian Cancer Registry (ECR) is a population-based registry that collects data on all cancer cases in Estonia. More information about ECR is available at the webpage of National
Outcomes Report: Accountability Measures and Quality Improvements
Outcomes Report: Accountability Measures and Quality Improvements The FH Memorial Medical Center s Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures.
Central Pathology Review and Tissue MicroArrays. Dr Lisa Storer Children s Brain Tumour Research Centre Nottingham
Central Pathology Review and Tissue MicroArrays Dr Lisa Storer Children s Brain Tumour Research Centre Nottingham What is a tissue microarray? Tissue microarrays (TMAs) consist of paraffin blocks in which
MCR: MANAGEMENT OF 2018 CHANGES. By: Maricarmen Traverso-Ortiz MPH, CGG, CTR
MCR: MANAGEMENT OF 2018 CHANGES By: Maricarmen Traverso-Ortiz MPH, CGG, CTR LEARNING OBJECTIVES Discuss a summary of the new changes for 2018 Overview of how the Maryland Cancer Registry is managing and
Neoplasms/Lymphoma/Leukemia
Neoplasms/Lymphoma/Leukemia Session Guidelines This is a 15 minute webinar session for CNC physicians and staff CNC holds webinars monthly to address topics related to risk adjustment documentation and
INTRODUCTION TO PATHOLOGICAL TECHNIQUES. 1. Types of routine biopsy procedures 2. Special exams (IHC, FISH)
INTRODUCTION TO PATHOLOGICAL TECHNIQUES 1. Types of routine biopsy procedures 2. Special exams (IHC, FISH) Biopsy-Indications Diffuse/multifocal lesions (neoplastic, inflammatory, etc) Etiology of the
Introduction to ICD-O-3 coding rules
Introduction to ICD-O-3 coding rules Weena Laddachayaporn, MD National Cancer Institute, Bangkok, Thailand ICD-O-3 The International Classification of Diseases for Oncology Is a coding system for primary
TEST MENU BY SPECIALTY
1 TEST MENU BY SPECIALTY Breast Pathology Surgical excisions, needle core biopsies, and plastic surgery accepted from all sites Assessment of margins Axillary lymph node dissections Sentinel lymph nodes
CODING PRIMARY SITE. Nadya Dimitrova
CODING PRIMARY SITE Nadya Dimitrova OUTLINE What is coding and why do we need it? ICD-10 and ICD-O ICD-O-3 Topography coding rules ICD-O-3 online WHAT IS CODING AND WHY DO WE NEED IT? Coding: to assign
Molecular Pathology of Lymphoma (Part 1) Rex K.H. Au-Yeung Department of Pathology, HKU
Molecular Pathology of Lymphoma (Part 1) Rex K.H. Au-Yeung Department of Pathology, HKU Lecture outline Time 10:00 11:00 11:15 12:10 12:20 13:15 Content Introduction to lymphoma Review of lymphocyte biology
Understanding your diagnosis. Dr Graham Collins Consultant Haemtologist Oxford University Hospitals
Understanding your diagnosis Dr Graham Collins Consultant Haemtologist Oxford University Hospitals Common questions I get asked What is lymphoma? What subtype do I have and what does that mean? What are
Case: The patient is a 73 year old woman with vague complaints of dyspepsia and abdominal pain. Upper endoscopy showed features of gastritis and a
Case: The patient is a 73 year old woman with vague complaints of dyspepsia and abdominal pain. Upper endoscopy showed features of gastritis and a nodular lesion in the body of the stomach. The patient
Comprehensive cancer cover
Retirement Investments Insurance Health Comprehensive cancer cover Life Insurance+ with critical illness and Critical Illness+ Cancer is one of the biggest fears for the British public This is why our
MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site
POLICY: PG0364 ORIGINAL EFFECTIVE: 04/22/16 LAST REVIEW: 07/26/18 MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site GUIDELINES This policy does not certify benefits or authorization
ANNUAL CANCER REGISTRY REPORT-2005
ANNUAL CANCER REGISTRY REPORT-25 CANCER STATISTICS Distribution of neoplasms Of a total of 3,115 new neoplasms diagnosed or treated at the Hospital from January 25 to December, 25, 1,473 were seen in males
List of Available TMAs in the PRN
TMA RPCI_BrainCa01 RPCI_BrCa03 RPCI_BrCa04 RPCI_BrCa05 RPCI_BrCa0 RPCI_BrCa07 RPCI_BrCa08 RPCI_BrCa15 RPCI_BrCa1 RPCI_BrCa17 RPCI_BrCa18 RPCI_BrCa19 RPCI_BrCa20 RPCI_BrCa21 RPCI_BrCa24 RPCI_BrCa25 RPCI_BrCa2
TRIPath FEE Schedule
TRIPath FEE Schedule (Effective 1/1/2018) CONSULTATIONS & START-UP FEES Project Service Fee UW Client Non-UW Client General Project Set-Up Fee* $75.00 $100.00 IHC single stain projects incur a per antibody
S2 File. Clinical Classifications Software (CCS). The CCS is a
S2 File. Clinical Classifications Software (CCS). The CCS is a diagnosis categorization scheme based on the ICD-9-CM that aggregates all diagnosis codes into 262 mutually exclusive, clinically homogeneous
Comprehensive cancer cover
Retirement Investments Insurance Health Comprehensive cancer cover Life Insurance+ with critical illness and Critical Illness+ Cancer is one of the biggest fears for the British public This is why our
CS 6824: Tissue-Based Map of the Human Proteome
CS 6824: Tissue-Based Map of the Human Proteome T. M. Murali November 17, 2016 Human Protein Atlas Measure protein and gene expression using tissue microarrays and deep sequencing, respectively. Alternative
Macmillan Publications
S1 S2 S3 S3 S3 S4 S5 S6 S7 S8 S8 S9 S10 S11 S11 S12 S13 S14 S15 S17 S18 S19 Bladder Cancer: Non-Invasive, Invasive and Advanced Bone Cancer: Primary, Secondary Colon Cancer, Anal Cancer, Rectal Cancer
Outcomes Report: Accountability Measures and Quality Improvements
Outcomes Report: Accountability Measures and Quality Improvements The s Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures. Because we are an accredited
Cancer Association of South Africa (CANSA)
Cancer Association of South Africa (CANSA) Fact Sheet on ICD-10 Coding of Neoplasms Introduction The International Statistical Classification of Diseases and Related Health Problems, 10 th Revision (ICD-10)
ACHIEVING EXCELLENCE IN ABSTRACTING: LYMPHOMA
ACHIEVING EXCELLENCE IN ABSTRACTING: LYMPHOMA ACHIEVING EXCELLENCE IN ABSTRACTING LYMPHOMA Recoding Audit Performed in 2009 260 cases audited 17 data items audited per case 4420 possible discrepancies
Patient underwent hemicolectomy: 7 x 4.5 cm intusscepted segment of ileum in colon - mucosal
Extranodal Lymphomas Rena Buckstein Odette Cancer Center Case: JT 69 yo male COO software company PMHx: basal cell back, cholesterol Presents to ER with severe abdominal pain, bloody diarrhea x 2d In ER
Cancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC
Cancers of unknown primary : Knowing the unknown Prof. Ahmed Hossain Professor of Medicine SSMC Definition Cancers of unknown primary site (CUPs) Represent a heterogeneous group of metastatic tumours,
A Probabilistic Approach for the Assessment of Internal Dose to Chronic Lymphocytic Leukemia Precursor Cells
A Probabilistic Approach for the Assessment of Internal Dose to Chronic Lymphocytic Leukemia Precursor Cells James W. Neton 1 A. Iulian Apostoaei 2 B. John R. Trabalka 2 1 U.S. National Institute for Occupational
NEOPLASIA-I CANCER. Nam Deuk Kim, Ph.D.
NEOPLASIA-I CANCER Nam Deuk Kim, Ph.D. 1 2 Tumor in the hieroglyphics of the Edwin Smith papyrus (1,600 B.C., Breasted s translation 1930) 3 War on Cancer (National Cancer Act, 1971) 4 Cancer Acts in Korea
155.2 Malignant neoplasm of liver not specified as primary or secondary. C22.9 Malignant neoplasm of liver, not specified as primary or secondary
ICD-9 TO ICD-10 Reference ICD-9 150.9 Malignant neoplasm of esophagus unspecified site C15.9 Malignant neoplasm of esophagus, unspecified 151.9 Malignant neoplasm of stomach unspecified site C16.9 Malignant
Cancer of lymph nodes survival rate
Cancer of lymph nodes survival rate Search 14-3-2016 Survival rates of pancreatic cancer are based on outcomes of people who've had the disease. Find the survival rates for pancreatic cancer here. 18-12-2017
CEA (CARCINOEMBRYONIC ANTIGEN)
(CARCINOEMBRYONIC ANTIGEN) 428 C15.3 Malignant neoplasm of upper third of esophagus C15.4 Malignant neoplasm of middle third of esophagus C15.5 Malignant neoplasm of lower third of esophagus C15.8 Malignant
Single and Multiplex Immunohistochemistry
Single and Multiplex Immunohistochemistry Steve Westra, BS Reagent Product Specialist Leica Biosystems IHC Theory Polyclonal vs Monoclonal Polyclonal reagents Detect a multitude of epitopes Batch to batch
Epidemiology in Texas 2006 Annual Report. Cancer
Epidemiology in Texas 2006 Annual Report Cancer Epidemiology in Texas 2006 Annual Report Page 94 Cancer Incidence and Mortality in Texas, 2000-2004 The Texas Department of State Health Services Texas Cancer
Workshop Case # 8 (H 4205/07)
Workshop Case # 8 (H 4205/07) 53 y old male patient had a history of gastrectomy 15 years earlier for gastric carcinoma.on routine sonographic and CT control an enlarged lymph node was detected in the
Contents. vii. Preface... Acknowledgments... v xiii
Contents Preface... Acknowledgments... v xiii SECTION I 1. Introduction... 3 Knowledge-Based Diagnosis... 4 Systematic Examination of the Lymph Node... 7 Cell Type Identification... 9 Cell Size and Cellularity...
WLH Tumor Frequencies between cohort enrollment and 31-Dec Below the Women Lifestyle and Health tumor frequencies are tabulated according to:
DESCRIPTION Below the Women Lifestyle and Health tumor frequencies are tabulated according to: Benign =171 (Cervix uteri) treated as not recorded =191 (non-melanoma skin cancer) treated as not recorded
WLH Tumor Frequencies between cohort enrollment and 31-Dec Below the Women Lifestyle and Health tumor frequencies are tabulated according to:
WLH Tumor Frequencies between cohort enrollment and 31-Dec 2012 DESCRIPTION Below the Women Lifestyle and Health tumor frequencies are tabulated according to: Benign =171 (Cervix uteri) treated as not
PD-L1 Analyte Control DR
Quality in Control PD-L1 Analyte Control DR PD-L1_PI_v2 Product Codes: HCL019, HCL020 and HCL021 Contents PD-L1 Analyte Control DR 2 What is PD-L1? 3 The Role of PD-L1 in Cancer 3 PD-L1 Assessment 4 PD-L1
FINALIZED SEER SINQ S MAY 2012
FINALIZED SEER SINQ S MAY 2012 : 20120039 Primary site/heme & Lymphoid Neoplasms: What site do I code this to and what rule applies? How did you arrive at this? Please advise. See discussion. Patient with
Q: In order to use the code 8461/3 (serous surface papillary) for ovary, does it have to say the term "surface" on the path report?
Q&A Session for Collecting Cancer Data: Ovary Q: In order to use the code 8461/3 (serous surface papillary) for ovary, does it have to say the term "surface" on the path report? A: We reviewed both the
Histopathological analysis of lymph nodes in patient with clinical lymphadenopathy cases
International Journal of Research in Medical Sciences Patel K et al. Int J Res Med Sci. 2016 May;4(5):1655-1660 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Research Article DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20161244
Quality in Control ALK-Lung Analyte Control (EML4-ALK) ALK-Lymphoma Analyte Control (NPM-ALK)
Quality in Control ALK-Lung Analyte Control (EML4-ALK) ALK-Lymphoma Analyte Control (NPM-ALK) 10 Product Codes: HCL007, HCL008 and HCL009 HCL010, HCL011 and HCL012 Page 1 of Contents 1. What is ALK?...
VDx: Unlocking Complex Diagnostics
VDx: Unlocking Complex Diagnostics VDx now offers PARR testing in-house on formalin-fixed tissue Complicated Case? Is this cat s chronic lymphocytic enteritis really chronic IBD or is this early small
The European Commission s science and knowledge service. Joint Research Centre
The European Commission s science and knowledge service Joint Research Centre Coding Primary Site and Tumour Morphology JRC-ENCR training course Copenhagen, 25 September 2018 Nadya Dimitrova Outline What
Presentation material is for education purposes only. All rights reserved URMC Radiology Page 1 of 98
Presentation material is for education purposes only. All rights reserved. 2011 URMC Radiology Page 1 of 98 Radiology / Pathology Conference February 2011 Brooke Koltz, Cytopathology Resident Presentation
Pearls and pitfalls in interpretation of lymphoid lesions in needle biopsies
Pearls and pitfalls in interpretation of lymphoid lesions in needle biopsies Megan S. Lim MD PhD University of Pennsylvania October 8, 2018 Objectives To understand how the trend toward less invasive lymph
objectives Pitfalls and Pearls in PET/CT imaging Kevin Robinson, DO Assistant Professor Department of Radiology Michigan State University
objectives Pitfalls and Pearls in PET/CT imaging Kevin Robinson, DO Assistant Professor Department of Radiology Michigan State University To determine the regions of physiologic activity To understand
IBD-Related Lymphoma
IBD-Related Lymphoma Larry Burgart MD Staff Pathologist, Allina Health and Minnesota Gastroenterology Clinical Professor of Pathology, University of Minnesota College of Medicine IBD-Related Lymphoma
Corporate Medical Policy
Corporate Medical Policy Microarray-based Gene Expression Testing for Cancers of Unknown File Name: Origination: Last CAP Review: Next CAP Review: Last Review: microarray-based_gene_expression_testing_for_cancers_of_unknown_primary
BREAST PATHOLOGY GROSSING GUIDELINES
THINGS TO CONSIDER: A. Please review ALL imaging and previous biopsies PRIOR to grossing any breast case. a. It may be helpful to draw out your own guide to assist when grossing B. Faxitron your breast
Abstract. Introduction. Salah Abobaker Ali
Sensitivity and specificity of combined fine needle aspiration cytology and cell block biopsy versus needle core biopsy in the diagnosis of sonographically detected abdominal masses Salah Abobaker Ali
Two Cases of Primary Gastric Lymphoma, Mucosa-Associated Lymphoid Tissue (MALT)-type
Med. J. Kagoshima Univ., Vol. 47, Suppl. 2. 93-96, November, 1995 Case Report Two Cases of Primary Gastric Lymphoma, Mucosa-Associated Lymphoid Tissue (MALT)-type Mitsuharu NOMOTO1, Hiroshi SHIRAHAMA1,
Oncology General Principles L A U R I E S I M A R D B R E A S T S U R G I C A L O N C O L O G Y F E L L O W D E C E M B E R
Oncology General Principles L A U R I E S I M A R D B R E A S T S U R G I C A L O N C O L O G Y F E L L O W D E C E M B E R 2 0 1 2 Objectives Discuss Diagnostic and staging strategies in oncology Know
SHN-1 Human Digestive Panel Test results
SHN-1 Human Digestive Panel Test results HN-30 tongue HN-24 salivary gland HN-12 larynx HN-28 esophagus HN-29 stomach HN-20 pancreas HN-13 liver HN-14 gall bladder HN-27-1 duodenum HN-27-2 ileum HN-27-3
Physician On-line Staging Application. Darlene Dale Head, PMH Cancer Registry
Physician On-line Staging Application Darlene Dale Head, PMH Cancer Registry NAACCR 2004 Outline Overview of Princess Margaret Hospital History of Staging at PMH Steps to On-Line Physician Staging at PMH
HISTOPATHOLOGY. Introduction
HISTOPATHOLOGY Introduction Contacts Services offered Pathology tissue request Laboratory hours Special instructions Histopathology reports List of specimens Introduction The Histopathology section of
SYLLABUS BDS I PROFESSIONAL GENERAL HUMAN ANATOMY INCLUDING EMBRYOLOGY AND HISTOLOGY
GENERAL HUMAN ANATOMY INCLUDING EMBRYOLOGY AND HISTOLOGY I. General Anatomy 1. Anatomical terms 2. Skin, superficial fascia & deep fascia 3. Cardiovascular system, portal system, collateral circulation
Cancer survival in Shanghai, China,
Cancer survival in Shanghai, China, 1992 1995 Xiang YB, Jin F and Gao YT Abstract The Shanghai cancer registry, established in 1963, is the oldest one in mainland China; cancer registration is entirely
Dr. dr. Primariadewi R, SpPA(K)
Curriculum Vitae Dr. dr. Primariadewi R, SpPA(K) Education : Medical Doctor from UKRIDA Doctoral Degree from Faculty of Medicine University of Indonesia Pathologist Specialist and Consultant from Faculty
11/8/2018 DISCLOSURES. I have NO Conflicts of Interest to Disclose. UTILTY OF DETECTING PATTERNS
Bharat N. Nathwani, M.D. City of Hope Medical Center Professor, Director of Pathology Consultation Services, 1500 East Duarte Road, Duarte, California, 91010 DISCLOSURES -------------------------------------------------------